Prior Art Litigation Search in Lund.

Prior art search Lund work is life-science and deep-tech work first, because the patents asserted against companies in this city protect long-acting drug formulations, antibodies, network-video imaging and nanowire semiconductors rather than the consumer software fought over in other European clusters. Lund is the Swedish anchor of Medicon Valley, the cross-Öresund life-science region, and home to Camurus, BioInvent, Genovis, the former AstraZeneca campus now trading as Medicon Village, plus Axis Communications, a large Sony R&D site and Lund University’s NanoLund and big-science neighbours MAX IV and the European Spallation Source. When one of those companies is sued, validity is not decided in Skåne: Swedish patent revocation and infringement run exclusively through the Patent and Market Court in Stockholm, European patents can be attacked at the Unified Patent Court’s Nordic-Baltic regional division, also seated in Stockholm and run entirely in English, or in a nine-month opposition at the European Patent Office. In these fields the reference that actually kills a claim is rarely another patent; it is a journal article, a clinical-trial registry entry, a conference poster or a facility technical report. PerspireIP builds that non-patent-literature record on the compressed clocks these forums impose.

Why prior art search Lund cases turn on non-patent literature

Every prior art search Lund matter begins with one question: where does the disclosure that defeats this claim actually live? In pharmaceuticals, antibodies, imaging and semiconductor physics, the answer is almost never another granted patent. The state of the art in these fields is set in peer-reviewed journals, clinical-trial registries, conference posters, sequence databases and facility publications, and it becomes public long before, or alongside, the patent that later gets asserted. A search confined to patent databases predictably misses the reference that decides the case.

The reason is structural. Researchers at Lund’s universities, hospitals, life-science firms and big-science facilities publish their work to establish priority, secure grants and win citations, frequently years before an equivalent idea reaches a patent filing. That public trail — a Lund University thesis, a Camurus formulation abstract, a NanoLund device paper, a MAX IV beamline commissioning report — is exactly what anticipates or renders obvious a later claim, and it is exactly what a patent-only search never reaches.

PerspireIP treats non-patent literature as the primary corpus rather than a supplement, then charts each reference against the asserted claim element by element, so counsel receives a filing-ready invalidity record instead of a raw list of database hits.

Lund’s Medicon Valley cluster: where the killer art lives

Lund anchors the Swedish half of Medicon Valley, the bi-national life-science region that spans southern Skåne and eastern Denmark across the Öresund and packs close to 600 life-science companies, nine research universities and dozens of hospitals into a compact footprint. At its centre sits Medicon Village, a science park carved out of the buildings AstraZeneca vacated in Lund and now home to roughly 180 organisations and thousands of employees. This is one of Europe’s densest concentrations of published biomedical work.

• Pharmaceuticals: Camurus, built on long-acting injectable depot formulations, and a broad drug-delivery base
• Antibodies and biologics: BioInvent, spun out of Lund University research, and a wider immuno-oncology cluster
• Enzymes and analytical tools: Genovis and a deep bioanalytical-reagent layer
• Medical devices: the dialysis and extracorporeal heritage of Gambro, founded in Lund and now part of Baxter
• Research base: Lund University’s faculty of medicine, Skåne University Hospital and the Medicon Village campus

That profile dictates what invalidity work looks like here. The patents that decide market entry are rarely the original molecule claims, which have usually expired. The fight is over the secondary layer — second-medical-use and dosage-regimen claims, long-acting depot and formulation claims, polymorphs and salts, antibody and manufacturing-process claims — and each type demands a different kind of prior art.

For a defendant or a generic and biosimilar launch team, that density cuts both ways. The asserted patent usually sits in a crowded, heavily documented field where earlier work by a rival, an academic group or the patentee’s own scientists is already on the public record, dated and ready to be turned into an invalidity theory. The task is to find it and prove exactly when it became available.

The killer references in a Lund pharma and biologics case

In a Lund life-science matter, the strongest references come from a predictable set of sources a patent-only search never reaches. Getting to them, and proving when each one became public, is the real work of the search.

• Journal and conference literature: peer-reviewed articles, congress abstracts and posters from ASCO, AACR, EHA and specialist meetings that disclose a dosage, formulation or mechanism first
• Clinical-trial registries: ClinicalTrials.gov and the EU Clinical Trials Register, whose dated protocol entries can anticipate a dosage-regimen or second-medical-use claim
• Sequence and structure data: GenBank, UniProt, the PDB and antibody databases for biologics and antibody claims
• Regulatory and quality disclosures: product labels, EMA and FDA assessment reports, and pharmacopoeia monographs for salts, polymorphs and excipients
• Academic grey literature: doctoral theses and dissertations from Lund University and its Medicon Valley partners, and prior public use at clinics and conferences

A thorough prior art litigation search in this sector has to reach all of these, because a single dated trial registry entry or congress poster can defeat the exact claim that would otherwise block a launch. The evidentiary hurdle is public availability: a bare date on an abstract is not enough, so we pin each reference to a verifiable pre-priority date using library accession records, registry timestamps, congress programmes and publisher metadata.

Swedish exclusivity also rarely ends when the patent term does, because a supplementary protection certificate can extend a medicinal product by up to five years, plus a possible paediatric extension. Because the SPC stands or falls with the basic patent behind it, testing that patent’s validity is the first thing a Lund launch plan has to do — and the prior-art record that clears it is the same record that supports any later court fight.

Photonics, semiconductors and imaging: a different prior-art corpus

Lund is not only a life-science town. Axis Communications, founded here in 1984, is a world leader in network video, access control and audio, and Sony maintains a large Lund R&D presence rooted in the former Sony Ericsson mobile operation, so Ericsson’s cellular heritage keeps standard-essential patents in the local bloodstream. Lund University’s NanoLund, long led in nanowire research by Lars Samuelson, is a global centre for III-V and III-nitride semiconductor work that has spun out ventures such as Hexagem, while MAX IV and the European Spallation Source have made the city a hub for advanced instrumentation.

Each field carries its own invalidity signature, and the decisive art sits in a different corpus from the pharma case.

• Network video and imaging: compression, encoding, image-sensor and computer-vision art, where product manuals, standards annexes and older camera firmware often anticipate
• Cellular SEPs: the exact 4G or 5G release, plus the 3GPP contributions, change requests and ETSI declarations behind a declared-essential claim
• Nanowire and III-nitride devices: NanoLund and IEEE papers, epitaxy and fabrication-process disclosures, and doctoral theses that are frequently the closest art
• Big-science instrumentation: neutron and X-ray detector, beamline and accelerator design reports and facility user publications from MAX IV and ESS

Much of this art is open-access but poorly indexed, and a meaningful slice sits in Swedish, German or French. For imaging and SEP disputes, invalidating even a single asserted patent can reshape the essentiality and rate analysis in a much larger FRAND negotiation, which is why the search interrogates the standard’s paper trail and the academic record alongside the patent literature.

Why a Lund patent dispute is heard in Stockholm

A Lund company sued over a patent will not litigate in Lund, or anywhere in Skåne. Since 2016 Sweden has concentrated all patent litigation in a single specialist forum: the Patent and Market Court (Patent- och marknadsdomstolen), a division of the Stockholm District Court, which holds exclusive first-instance jurisdiction over patent validity and infringement nationwide. Appeals go to the Patent and Market Court of Appeal within the Svea Court of Appeal, also in Stockholm, with a limited further route to the Supreme Court.

Two features of the venue shape the search. First, the bench pairs legally qualified judges with technically and economically expert members, so a well-charted invalidity record built on journal, clinical and standards literature lands with a panel equipped to read it. Second, a Swedish revocation or invalidity action attacks a national patent, or the Swedish part of a European patent, on the familiar grounds of lack of novelty, lack of inventive step, insufficiency or added matter. On inventive step the court closely follows EPO case law and the problem-and-solution approach, so a record built to EPO standards travels straight into a Stockholm courtroom.

Swedish patents are granted by PRV, the Swedish Intellectual Property Office in Stockholm, and a national patent can be revoked only through the Patent and Market Court. Because one specialised court hears every meaningful Swedish validity fight, the quality of the prior art is decisive: the panel expects references charted element by element against the asserted claims, not a keyword dump, and the evidence has to be court-ready before a Stockholm judge ever reads it.

Three routes to invalidate a patent asserted against a Lund defendant

A Lund defendant facing an asserted patent typically has three forums in which to attack validity, and each carries its own rules, clocks and territorial reach. Choosing among them is a strategic decision for your litigation counsel, but all three draw on the same underlying prior-art record.

• Swedish revocation. An invalidity action or counterclaim before the Patent and Market Court in Stockholm, the sole first-instance venue, removing the Swedish patent or the Swedish part of a European bundle, with appeals to the Patent and Market Court of Appeal.
• UPC revocation. A central revocation action or counterclaim before the Unified Patent Court’s Nordic-Baltic regional division, seated in Stockholm and conducted in English, whose ruling reaches every participating member state at once, for European patents not opted out.
• EPO opposition. A centralised opposition at the European Patent Office, available only within nine months of the mention of grant, deciding validity for every state where the patent was validated.

The UPC option is distinctly favourable for southern Sweden. The Nordic-Baltic division is the court’s only regional division, shared by Sweden, Estonia, Latvia and Lithuania, and unusually its sole language of proceedings is English — even though English is an official language of none of the four states. That makes a revocation strikingly accessible to the international teams that run IP across Medicon Valley and the Öresund.

Because opposition, national revocation and UPC proceedings can run in parallel, and because a full patent invalidation theory has to survive whichever forum is chosen, we build one evidence base that all three routes can use rather than searching the same field three times. At the EPO in particular, the obviousness of a claim is judged on the problem-and-solution approach, so the prior art has to be mapped to the closest disclosure precisely.

How PerspireIP builds a Lund invalidity record

We start from the claims, not the keywords. A prior art search Lund defendant relies on has to be organised the way a Swedish revocation defence, a UPC revocation annex or an EPO opposition notice needs it, so each asserted claim is broken into elements, the priority date that actually governs each claim is fixed, and each element is mapped to the art that reads on it as of that date.

• Element-by-element claim charts aligned to the EPO problem-and-solution approach and Swedish revocation grounds
• Structure, Markush, sequence and reaction searching for pharmaceutical, antibody and biologics claims
• Clinical-trial registries, congress abstracts, pharmacopoeias, labels and regulatory assessment reports
• Standards contributions, specifications and product documentation for imaging, telecom SEP and instrumentation disputes
• Swedish, Danish, German and French-language art, and grey literature such as theses and facility reports, that national searches routinely miss
• A written invalidity memo that grades the strength of each reference rather than just listing it

We work under confidentiality as a search partner to your Swedish litigation counsel and patent attorneys, to the court and office deadlines that govern each forum, and the work often runs alongside a defensive patent infringement analysis so validity and non-infringement positions come from one consistent evidence base. Because the venue is in Stockholm while the technology and instructing team are usually in Lund, we are used to bridging that distance and coordinating cleanly with counsel at both ends.

We are candid about what we find. A search that surfaces only weak art is worth knowing early, while settlement, design-around and licensing options are still open and inexpensive, and our memos grade references honestly rather than overselling a case a defendant is about to bet a product line on.

IP Landscape & Resources in Lund

Key intellectual-property authorities and venues relevant to Lund:

• PRV (Swedish Intellectual Property Office) — the Swedish national office that grants and registers Swedish patents, trademarks and designs
• Patent and Market Court (Patent- och marknadsdomstolen) — Sweden's sole first-instance venue for patent validity and infringement, a division of Stockholm District Court
• Unified Patent Court (UPC) — its Nordic-Baltic regional division is seated in Stockholm and conducts revocation proceedings in English
• European Patent Office (EPO) — grants European patents covering Sweden and hears centralised oppositions filed within nine months of grant

Request a Prior Art Search in Lund

Explore related PerspireIP services: Prior Art Litigation Search · Patent Invalidation · Patent Infringement Analysis.

Frequently Asked Questions